2017 NVCA Yearbook Highlights Busy Year for Venture Industry and NVCA

20 March 2017

National Venture Capital Association

The National Venture Capital Association (NVCA) today released the 20th edition of the annual NVCA Yearbook, documenting trends and analysis of venture capital activity in the United States from the past year and capturing historical data and information about venture’s role in fueling entrepreneurship in America. The report shows that the number of life science deals as a share of overall venture deal count increased to 12.5% in 2016.

"While the overall number of investments (1,016) and venture dollars invested ($11.7 billion) into life science companies (defined as pharmaceuticals, biotechnology, and healthcare devices and supplies) declined year-over-year, the number of life science deals as a share of overall venture deal count increased to 12.5% in 2016. Notable investments into venture-backed life science companies included: Moderna, a drug developer for genetic disorders, hemophilic and blood factors, and oncology; Human Longevity, a developer of genomics and cell therapy-based diagnostic and therapeutic technology; and CVRx, a developer of implantable technology for the treatment of high blood pressure and heart failure."


General Industry Statistics

Commitments to Venture Funds

Capital Deployed to Startups

Exit Landscape

Source - NVCA

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more